Journal Scope and Content
/// Full-Length Articles
/// Brief Reviews
/// Cutting Edge Articles
/// In This Issue
/// Immunology Notes and Resources
/// Letters to the Editor
/// Pillars of Immunology
/// Translating Immunology
/// Next in The JI
Full-Length Articles: The JI publishes peer-reviewed manuscripts describing novel findings in all areas of experimental immunology, including both basic and clinical studies.
Articles are published in the following sections:
/// Allergy and Other Hypersensitivities
/// Antigen Recognition and Responses
/// Clinical and Human Immunology
Manuscripts submitted to the Clinical and Human Immunology section will be reviewed mindful of the limitations in sample size and depth of mechanistic analyses that may be inherent to these types of studies.
/// Immune Regulation
/// Immune System Development
/// Immunotherapy and Vaccines
/// Infectious Disease and Host Response
/// Innate Immunity and Inflammation
/// Molecular and Structural Immunology
/// Mucosal Immunology
/// Systems Immunology
Manuscripts submitted to the “Systems Immunology” section should center on analyses of novel large data sets, generated by the authors, which will serve as useful resources for future work in the field. The authors’ informatics analyses should allow them to draw concrete conclusions, supported by the data, about the biology of the system(s) under study. Alternatively, manuscripts may describe a novel method of data analysis, which could be applied to publicly available data sets. The latter type of manuscript must convincingly demonstrate the utility of the new analysis method to reveal novel biological insights about the system(s) under study. However, it is not necessary for either type of manuscript to include definitive mechanistic analysis or experiments beyond those necessary for the acquisition of reproducible and meaningful data sets.
/// Tumor Immunology
/// Novel Immunological Methods (see Editorial)
Manuscripts submitted to the Novel Immunological Methods section should provide a new approach to important immunological problems. The manuscript should validate the technique, reagent, or genetically manipulated line of mice (and provide data on that) and indicate their utility for solving an immunologically interesting problem, but it is not necessary for the manuscript to solve that problem. The manuscript is evaluated on whether the technique, reagent, or line of mice is better than what is currently available and could therefore advance the field, as well as the usefulness of the technique, reagent, or line of mice to the field.
As a point of reference, descriptions of the following would only be appropriate if they provide innovative insight into unresolved immunological problems, reveal novel structural features that are unique in an immunologically relevant manner, or represent major breakthroughs in the field:
/// New reagents
/// T cell or B cell epitopes
/// Peptide binding motifs for previously uncharacterized MHC products
/// Structures of MHC allelic products or MHC-peptide complexes not previously crystallized or homologs from previously uncharacterized species
/// Three-dimensional structures of allergens or other antigens, antibody-defined epitopes, or antigen-antibody complexes
/// Comparative analysis of proteins of immunological interest (intra- or inter-species comparisons)
/// Research techniques
/// Clinical case reports
Those wishing to report the identification of epitopes may do so at the Immune Epitope Database and Analysis Resource.